Today marks the official launch of our newest platform, Responsum for Long COVID. This free knowledge and empowerment platform provides personalized patient information, resources, and support for people with long
Update, Feb. 10, 2021: “Galapagos NV and Gilead Sciences today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with
Responsum Health has the honor of partnering up with the IgA Nephropathy Foundation, a patient-focused non-profit organization for Immunoglobulin A nephropathy (IgAN) dedicated to both the funding of research for
The Responsum Health community is growing again! We’re proud to announce a new partnership to fight glaucoma with Prevent Blindness—an organization, founded in 1908, whose mission is to prevent blindness
Cookies are small bits of information that we might place on your computer. We use them to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.